Journal of Dental Anesthesia and Pain Medicine

The Korean Dental Society of Anesthsiology (대한치과마취과학회)
권호 표지
DOI QR코드

DOI QR Code

Resistance to local anesthesia in people with the Ehlers-Danlos Syndromes presenting for dental surgery

  • Schubart, Jane R. (Department of Surgery, The Pennsylvania State University, College of Medicine) ;
  • Schaefer, Eric (Department of Public Health Sciences, The Pennsylvania State University, College of Medicine) ;
  • Janicki, Piotr (Department of Anesthesiology and Perioperative Medicine, The Pennsylvania State University, College of Medicine) ;
  • Adhikary, Sanjib D. (Department of Anesthesiology and Perioperative Medicine, The Pennsylvania State University, College of Medicine) ;
  • Schilling, Amber (Department of Surgery, The Pennsylvania State University, College of Medicine) ;
  • Hakim, Alan J. (The Wellington Hospital, Platinum Medical Centre) ;
  • Bascom, Rebecca (Department of Public Health Sciences, The Pennsylvania State University, College of Medicine) ;
  • Francomano, Clair A. (Medical and Molecular Genetics, Indiana University School of Medicine) ;
  • Raj, Satish R. (Vanderbilt University Medical Center)
  • Received : 2019.08.21
  • Accepted : 2019.09.27
  • Published : 2019.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: People with the Ehlers-Danlos Syndromes (EDS), a group of heritable disorders of connective tissue, often report experiencing dental procedure pain despite local anesthetic (LA) use. Clinicians have been uncertain how to interpret this apparent LA resistance, as comparison of EDS and non-EDS patient experience is limited to anecdotal evidence and small case series. The primary goal of this hypothesis-generating study was to investigate the recalled adequacy of pain prevention with LA administered during dental procedures in a large cohort of people with and without EDS. A secondary exploratory aim asked people with EDS to recall comparative LA experiences. Methods: We administered an online survey through various social media platforms to people with EDS and their friends without EDS, asking about past dental procedures, LA exposures, and the adequacy of procedure pain prevention. Among EDS respondents who both received LA and recalled the specific LA used, we compared agent-specific pain prevention for lidocaine, procaine, bupivacaine, mepivacaine, and articaine. Results: Among the 980 EDS respondents who had undergone a dental procedure LA, 88% (n = 860) recalled inadequate pain prevention. Among 249 non EDS respondents only 33% (n = 83) recalled inadequate pain prevention (P < 0.001 compared to EDS respondents). The agent with the highest EDS-respondent reported success rate was articaine (30%), followed by bupivacaine (25%), and mepivacaine (22%). Conclusions: EDS survey respondents reported nearly three times the rate of LA non-response compared to non-EDS respondents, suggesting that LAs were less effective in preventing their pain associated with routine office dental procedures.

Keywords

References

  1. Fikree A, Aktar R, Morris JK, Grahame R, Knowles CH, Aziz Q. The association between Ehlers-Danlos syndrome-hypermobility type and gastrointestinal symptoms in university students: a cross-sectional study. Neurogastroenterol Motil 2017; 29: e12942. https://doi.org/10.1111/nmo.12942
  2. Murray B, Yashar BM, Uhlmann WR, Clauw DJ, Petty EM. Ehlers-Danlos syndrome, hypermobility type: A characterization of the patients' lived experience. Am J Med Genet A 2013; 161A: 2981-8.
  3. Schubart JR, Schaefer E, Hakim AJ, Francomano CA, Bascom R. Use of cluster analysis to delineate symptom profiles in Ehlers-Danlos syndrome patient population. J Pain Symptom Manage 2019; 58: 427-36. https://doi.org/10.1016/j.jpainsymman.2019.05.013
  4. Castori M, Tinkle B, Levy H, Grahame R, Malfait F, Hakim A. A framework for the classification of joint hypermobility and related conditions. Am J Med Genet C Semin Med Genet 2017; 175: 148-57. https://doi.org/10.1002/ajmg.c.31539
  5. Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet 2017; 175: 8-26. https://doi.org/10.1002/ajmg.c.31552
  6. Chopra P, Tinkle B, Hamonet C, Brock I, Gompel A, Bulbena A, et al. Pain management in the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet 2017; 175: 212-9. https://doi.org/10.1002/ajmg.c.31554
  7. Voermans NC, Knoop H, Bleijenberg G, van Engelen BG. Pain in ehlers-danlos syndrome is common, severe, and associated with functional impairment. J Pain Symptom Manage 2010; 40: 370-8. https://doi.org/10.1016/j.jpainsymman.2009.12.026
  8. Schubart JR, Schilling A, Schaefer E, Bascom R, Francomano C. Use of prescription opioid and other drugs among a cohort of persons with Ehlers-Danlos syndrome: A retrospective study. Am J Med Genet A 2019; 179: 397-403. https://doi.org/10.1002/ajmg.a.61031
  9. Arendt-Nielsen L, Kaalund S, Bjerring P, Hogsaa B. Insufficient effect of local analgesics in Ehlers Danlos type III patients (connective tissue disorder). Acta Anaesthesiol Scand 1990; 34: 358-61. https://doi.org/10.1111/j.1399-6576.1990.tb03103.x
  10. Arendt-Nielsen L, Kaalund S, Hogsaa B, Bjerring P, Grevy C. The response to local anaesthetics (EMLA-cream) as a clinical test to diagnose between hypermobility and Ehlers Danlos type III syndrome. Scand J Rheumatol 1991; 20: 190-5. https://doi.org/10.3109/03009749109103020
  11. Hakim AJ, Grahame R, Norris P, Hopper C. Local anaesthetic failure in joint hypermobility syndrome. J R Soc Med 2005; 98: 84-5. https://doi.org/10.1177/014107680509800222
  12. The Ehlers-Danlos Society. EDS Comorbidity Coalition. [cited October 2017]; Available from: https://www.ehlers-danlos.com/eds-comorbidity-coalition/
  13. Patient-centered Outcomes Research Institute. PCORI Methodology Standards. [cited 08/14/2019]; Available from: https://www.pcori.org/research-results/about-ourresearch/research-methodology/pcori-methodology-standards. Posted November 12, 2015; updated February 26, 2019.
  14. Vreeland DL, Reader A, Beck M, Meyers W, Weaver J. An evaluation of volumes and concentrations of lidocaine in human inferior alveolar nerve block. J Endod 1989; 15: 6-12. https://doi.org/10.1016/S0099-2399(89)80091-3
  15. Nist RA, Reader A, Beck M, Meyers WJ. An evaluation of the incisive nerve block and combination inferior alveolar and incisive nerve blocks in mandibular anesthesia. J Endod 1992; 18: 455-9. https://doi.org/10.1016/S0099-2399(06)80849-6
  16. Ridenour S, Reader A, Beck M, Weaver J. Anesthetic efficacy of a combination of hyaluronidase and lidocaine with epinephrine in inferior alveolar nerve blocks. Anesth Prog 2001; 48: 9-15.
  17. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377-81. https://doi.org/10.1016/j.jbi.2008.08.010
  18. Marhofer D, Karmakar MK, Marhofer P, Kettner SC, Weber M, Zeitlinger M. Does circumferential spread of local anaesthetic improve the success of peripheral nerve block? Br J Anaesth 2014; 113: 177-85. https://doi.org/10.1093/bja/aeu002
  19. St George G, Morgan A, Meechan J, Moles DR, Needleman I, Ng YL, et al. Injectable local anaesthetic agents for dental anaesthesia. Cochrane Database Syst Rev 2018; 7: CD006487.
  20. Trescot AM. Local anesthetic "resistance". Pain Physician 2003; 6: 291-3. https://doi.org/10.36076/ppj.2003/6/291
  21. Badr N, Aps J. Efficacy of dental local anesthetics: A review. J Dent Anesth Pain Med 2018; 18: 319-32. https://doi.org/10.17245/jdapm.2018.18.6.319
  22. Bennett DL, Clark AJ, Huang J, Waxman SG, Dib-Hajj SD. The role of voltage-gated sodium channels in pain signaling. Physiol Rev 2019; 99: 1079-151. https://doi.org/10.1152/physrev.00052.2017
  23. Fang P, Tang PF, Xu RA, Zheng X, Wen J, Bao SS, et al. Functional assessment of CYP3A4 allelic variants on lidocaine metabolism in vitro. Drug Des Devel Ther 2017; 11: 3503-10. https://doi.org/10.2147/DDDT.S152366
  24. Oliver DW, Balan KK, Burrows NP, Hall PN. Dispersal of radioisotope labelled solution following deep dermal injection in Ehlers-Danlos syndrome. Br J Plast Surg 2000; 53: 308-12. https://doi.org/10.1054/bjps.2000.3338
  25. Aktar R, Peiris M, Fikree A, Cibert-Goton V, Walmsley M, Tough IR, et al. The extracellular matrix glycoprotein tenascin-X regulates peripheral sensory and motor neurones. J Physiol 2018; 596: 4237-51. https://doi.org/10.1113/JP276300
  26. Aktar R, Peiris M, Fikree A, Eaton S, Kritas S, Kentish SJ, et al. A novel role for the extracellular matrix glycoprotein-Tenascin-X in gastric function. J Physiol 2019; 597: 1503-15. https://doi.org/10.1113/JP277195
  27. Vieira WA, Paranhos LR, Cericato GO, Franco A, Ribeiro MAG. Is mepivacaine as effective as lidocaine during inferior alveolar nerve blocks in patients with symptomatic irreversible pulpitis? A systematic review and meta-analysis. Int Endod J 2018; 51: 1104-17. https://doi.org/10.1111/iej.12926
  28. Sampaio RM, Carnaval TG, Lanfredi CB, Horliana AC, Rocha RG, Tortamano IP. Comparison of the anesthetic efficacy between bupivacaine and lidocaine in patients with irreversible pulpitis of mandibular molar. J Endod 2012; 38: 594-7. https://doi.org/10.1016/j.joen.2012.01.008
  29. Su N, Wang H, Zhang S, Liao S, Yang S, Huang Y. Efficacy and safety of bupivacaine versus lidocaine in dental treatments: a meta-analysis of randomised controlled trials. Int Dent J 2014; 64: 34-45. https://doi.org/10.1111/idj.12060
  30. Visconti RP, Tortamano IP, Buscariolo IA. Comparison of the anesthetic efficacy of mepivacaine and lidocaine in patients with irreversible pulpitis: a double-blind randomized clinical trial. J Endod 2016; 42: 1314-9. https://doi.org/10.1016/j.joen.2016.06.015
  31. Seneviratne SL, Maitland A, Afrin L. Mast cell disorders in Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet 2017; 175: 226-36. https://doi.org/10.1002/ajmg.c.31555
  32. Magadmi R, Meszaros J, Damanhouri ZA, Seward EP. Secretion of mast cell inflammatory mediators is enhanced by CADM1-dependent adhesion to sensory neurons. Front Cell Neurosci 2019; 13: 262.
  33. Castori M. Pain in Ehlers-Danlos syndromes: manifestations, therapeutic strategies and future perspectives. Expert Opin Orphan Drugs 2016; 4: 1145-58. https://doi.org/10.1080/21678707.2016.1238302
  34. Fossataro C, Bucchioni G, D'Agata F, Bruno V, Morese R, Krystkowiak P, et al. Anxiety-dependent modulation of motor responses to pain expectancy. Soc Cogn Affect Neurosci 2018; 13: 321-30. https://doi.org/10.1093/scan/nsx146
  35. Drasner K. Local Anesthetics. In: Basic & Clinical Pharmacology. 14th ed.. Edited by Katzung BG. New York, McGraw-Hill Education. 2017.

Cited by

  1. Local anaesthetic resistance in a patient with Ehlers‐Danlos syndrome undergoing caesarean section with continuous spinal anaesthesia vol.8, pp.1, 2019, https://doi.org/10.1002/anr3.12040
  2. Ehlers-Danlos syndrome vol.229, pp.3, 2019, https://doi.org/10.1038/s41415-020-2019-3
  3. Leveraging Digital Technology for Treatment of Young Patients with Congenital Conditions: A Clinical Report vol.30, pp.suppl2, 2019, https://doi.org/10.1111/jopr.13241
  4. A Proposed Approach for Conducting Studies That Use Data From Social Media Platforms vol.96, pp.8, 2021, https://doi.org/10.1016/j.mayocp.2021.02.010
  5. Oral manifestations of Ehlers‐Danlos syndromes vol.187, pp.4, 2019, https://doi.org/10.1002/ajmg.c.31941
  6. The power of patient‐led global collaboration vol.187, pp.4, 2019, https://doi.org/10.1002/ajmg.c.31942
  7. Neurodevelopmental atypisms in the context of joint hypermobility, hypermobility spectrum disorders, and Ehlers–Danlos syndromes vol.187, pp.4, 2019, https://doi.org/10.1002/ajmg.c.31946
  8. Throat and voice problems in Ehlers–Danlos syndromes and hypermobility spectrum disorders vol.187, pp.4, 2019, https://doi.org/10.1002/ajmg.c.31956